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ABSTRACT
Background: Treatment options for melanoma
in situ (MIS) include imiquimod, radiation
therapy, cryotherapy, excisional and Mohs
surgery. Ingenol mebutate is a new topical
treatment option recognized for actinic
keratosis. Although in vitro effectiveness has
been demonstrated on melanoma cell lines, its
therapeutic potential for in vivo melanomas is
unknown.
Case Report: In 2011, a 91-year-old woman
presented a thick melanoma of her cheek. The
lateral sections revealed persisting in situ
melanoma, which were again excised. She
presented for follow-up and a recurrent MIS
was evidenced centered on the previous scar.
She refused further surgery and ingenol
mebutate (0.015% gel) was administered on
three consecutive days. One month later, a
complete clinical resolution was observed.
Histology and immunohistology revealed no
residual MIS.
Conclusion: In this patient, ingenol mebutate
was successful and well-tolerated as a topical,
alternative therapy for MIS after failure of other
treatment options.
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INTRODUCTION
Ingenol mebutate (a macrocyclic diterpene
ester, PEP005, 0.015%) derives from the sap of
the plant Euphorbia peplus. This herb has been
used of old as a traditional remedy for skin
cancers. Ingenol mebutate is currently an US
Food and Drug Administration (FDA) and
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European Medicines Agency (EMA) recognized
field-directed treatment for actinic keratosis
[1, 2]. Ingenol mebutate activates a broad
range of protein kinase C (PKC) (a, b, c, d, e, g
and h) isoenzymes [3]. Direct pro-apoptotic
effects of this drug have been demonstrated in
several malignant cells, including melanoma
cell lines. Micromolar concentrations of ingenol
mebutate are required to kill melanoma cells via
PKC-independent secondary necrosis [3].
Topical application of ingenol mebutate was
revealed as being effective for human and
murine melanoma in mouse models [3]. In
transformed keratinocytes, ingenol mebutate
leads to cell death. Furthermore, ingenol
mebutate promotes an inflammatory infiltrate
that kills remaining tumor cells. It has been
demonstrated that ingenol mebutate does not
mediate cytotoxicity by a simple lytic, necrotic
mechanism, but activates distinct processes
involving multiple cell organelles in a cell-type
and differentiation-dependent manner [4].
In vitro experiments revealed epidermal cell
death, acute inflammation, recruitment of
neutrophils, hemorrhage, and eschar
formation when ingenol mebutate was tested
on keratinocytic cell lines and squamous cell
cancer cell lines [5, 6]. Currently, the action
mechanism of ingenol mebutate is divided into
three consecutive steps; (1) a direct effect of the
drug on the initial cancer accompanied by an
in situ production of pro-inflammatory
cytokines, (2) neutrophil infiltration, and (3)
induction of tumor-reactive antibodies,
diminishing potential relapses by antibody-
dependent neutrophil cytotoxicity [3].
However, as far as the authors are aware, no
published data are available on a potential effect
of ingenol mebutate on in vivo melanoma.
Melanoma in situ (MIS) is the most
superficial form of melanoma [7, 8]. There are
different treatment options including topical
immunotherapy by imiquimod, topical
destructive treatment by cryotherapy,
superficial radiotherapy and excisional or
Mohs surgery, all presenting their respective
advantages and inconveniencies. Some patients
do not qualify anymore for surgery for various
reasons and topical treatments are then
preferred.
This case report describes an elderly woman
with two previous large excisions of thick
melanoma on her cheek who refused further
surgery for recurrent MIS on the surgical scars.
CASE REPORT
A 91-year-old woman presented with 2 biopsy-
proven recurrent MISs in the direct vicinity of a
scar on her right cheek (Fig. 1). In 2011, she was
diagnosed with a superficial melanoma of the
right cheek (0.14 mm depth, Clark II, KI67:
10%, 1 mitosis/mm2, with micro metastases)
arising from an MIS and a nodular melanoma of
the right cheek (4 mm depth, Clark V, KI67:
30%, [5 mitoses/mm2) (Fig. 2). A wide surgical
excision was performed respecting 2 cm surgical
margins. The patient refused further workup for
staging and was followed in the dermatology
department. One year later, she presented a
recurrent nodular melanoma. Again, wide
surgery was performed. Histology revealed a
nodular melanoma (1, 93 mm depth, Clark IV,
KI67: 30%, 3 mitoses/mm2, with micro
metastases). Further physical examination was
unremarkable. Due to her age and her own
wishes, no further staging examinations were
performed. Two years later, she presented with
2 recurrent MISs adjacent to the surgical scar
(Fig. 2). A 4-mm punch biopsy confirmed the
diagnosis of MIS of the lentigo maligna
melanoma type. Again the patient and her
family refused categorically any further
132 Dermatol Ther (Heidelb) (2014) 4:131–135
surgical intervention and the authors decided to
attempt to treat these lesions with ingenol
mebutate gel 0.015%, based on in vitro data
on melanoma cell lines [3]. Three consecutive
daily applications were performed on the lesion
area. On the day of the third application, a
moderately crusting and oozing reaction was
observed. According to the severity scale
assessing ingenol mebutate toxicity, the
composite score was 9/24 (erythema: 1, flaking
or scaling: 2, crusting: 4, swelling: 2,
vesiculation or postulation: 0 and erosion or
ulceration: 0) [9]. Topical disinfection and
topical antibiotic ointment were
recommended and the crust disappeared after
1 week. One month later, there was a clinical
resolution of both lesions, with a slightly
squamous, post-inflammatory erythema
(Fig. 3). A cutaneous biopsy proved the
absence of residual MIS on histology (Fig. 4)
and on using immunohistochemistry with NKI-
C3, S100a, HMB45 and Melan A (DAKO,
Glostrup, Denmark) (Fig. 5). The local
tolerance of the treatment was acceptable for
the patient and no systemic signs were
observed. After 6 months of follow-up the
patient was still free of MIS recurrence.
DISCUSSION
Standard care for MIS is surgical excision or Mohs
surgery respecting a margin of 5–9 mm of
Fig. 1 Recurrent in situ melanomas in 2013
Fig. 2 Clinical aspect of the melanoma on the right cheek
in 2011
Fig. 3 Clinical aspect 1 month after treatment with
ingenol mebutate
Fig. 4 Histology (H/E 910) showing dermal ﬁbrosis
without any evidence of residual in situ melanoma
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clinically non-involved healthy skin [7].
However, alternative treatment options for MIS
are sometimes required for different reasons.
Either the patient refuses excisional surgery or
surgery is no longer recommended due to
morbidity and/or cosmetic considerations [8].
Furthermore, older age, multiple previous
surgical procedures, medical comorbidities may
preclude from surgery. The non-invasive
treatment options for MIS include local
radiation therapy and topical immunotherapy.
Occasionally cryotherapy or cryosurgery could
also be advocated.
Radiation therapy uses either Grenz rays or
soft X-rays. Although published cure rates
achieving 86% to 95%, it remains an
uncommonly used treatment option for MIS
in poor candidates for surgery.
Imiquimod is a synthetic imidazoquinoline
amine and acts as a toll-like receptor (TLR)
agonist on TLR7 and TLR8 [7–11]. This topical
immunomodulator increases, after binding to
the TLR’s, the endogenous production of
interferon-alpha, exhibiting anticancer
properties, interleukins (ILs) 6 and 12, as well
as tumor necrosis factor alpha [7, 8]. Evidence-
based medicine data on imiquimod and MIS are
scarce. Most publications deal with small case
series and case reports [6]. A recent meta-
analysis showed an average clearance rate of
91% with a histological proof [7]. However, the
follow-up periods were usually short, the
‘‘negative biopsy’’ did not preclude persisting
areas of MIS and particular attention should be
given to invasive melanoma progression after
an initial superficial tumor clearing.
There is no standard recommendation on
dosing and application protocols of imiquimod
and adaptations are often required to minimize the
local adverse reactions, consisting of moderate to
severe erythema, crusting, and sometimes oozing,
usually occurring after 2–3 weeks of treatment.
Systemic effects may sometimes be observed in the
form of flu-like symptoms with fever, headache,
hyperesthesia, myalgia and fatigue.
In sum, the long-term cure rates of
imiquimod are questionable [7] and caution is
advocated not to fail a subsequent diagnosis of
residual or recurrent invasive melanoma [7].
This case report suggests that in some
selected patients with MIS, ingenol mebutate
could be considered as an alternative treatment.
It could present the advantage over imiquimod
not to display potential systemic flu-like
symptoms. Furthermore, although cutaneous
adverse effects are common for both agents,
they are usually shorter in duration with
ingenol mebutate.
Dosing regimens, treatment efficacy and
tolerance should be evaluated on larger series.
Further research on the ‘‘cytotoxicity/
inflammation’’ mechanisms of action of
ingenol mebutate on in vivo melanocytic
tumors is warranted.
CONCLUSION
Ingenol mebutate merits to be considered as an
alternative treatment option for MIS in selected
Fig. 5 Melan A immunostaining (920) revealing no
evidence of recurrent melanoma in situ
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patients, after other therapies have failed.
Patients should be followed closely to detect
eventual recurrent deep invasion of melanoma.
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